πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10829460

[6,6] fused bicyclic HDAC8 inhibitors

Valo Early Discovery, Inc. Β· Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10829461

3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

Valo Early Discovery, Inc. Β· Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10829485

ATF6 inhibitors and uses thereof

BLACK BELT TX LTD Β· Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10829462

3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

Valo Early Discovery, Inc. Β· Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10829488

N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10822301

3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of g

Northwestern University Β· Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10822316

3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

Valo Early Discovery, Inc. Β· Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10822337

TGF-Ξ² inhibitorC

Rigel Pharmaceuticals, Inc. Β· Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10821178

Methods of treating biofilm infections comprising administering inhibitors of myeloid-deri

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10814010

FOXC2 inhibitor and methods of use thereof

The Board of Regents of the University of Texas System Β· Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10813929

Treating cancer with ATR inhibitors

Vertex Pharmaceuticals Incorporated Β· Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10815206

RIP1 inhibitory compounds and methods for making and using the same

Rigel Pharmaceuticals, Inc. Β· Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10815239

Compounds useful as inhibitors of ATR kinase

Vertex Pharmaceuticals Incorporated Β· Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10813934

Sirtuin modulators as inhibitors of cytomegalovirus

THE TRUSTEES OF PRINCETON UNIVERSITY Β· Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10815271

Structure-based peptide inhibitors of alpha-synuclein aggregation

The Regents of the University of California Β· Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10806730

Methods of treating cancer with farnesyltransferase inhibitors

Kura Oncology, Inc. Β· Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10806794

Protease inhibitors having enhanced features

Nektar Therapeutics Β· Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10808010

Peptide inhibitors of phosphoglycerate mutase and methods of use

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10800774

Heterocyclic inhibitors of ATR kinase

The Board of Regents of the University of Texas System Β· Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10800769

Heterocyclic inhibitors of ATR kinase

The Board of Regents of the University of Texas System Β· Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10800782

Inhibitors of cellular metabolic processes

Agios Pharmaceuticals, Inc. Β· Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10800781

Compounds useful as inhibitors of ATR kinase

Vertex Pharmaceuticals Incorporated Β· Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10793543

Selective C-KIT kinase inhibitor

HEFEI GRACEVO BIO-MEDICINE CO., LTD Β· Granted Tue Oct 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10793563

GCN2 inhibitors and uses thereof

Vertex Pharmaceuticals Incorporated Β· Granted Tue Oct 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted